The company is concentrating its R&D efforts in high-unmet-need areas like oncology and immunology, utilizing advanced, data-intensive platforms such as cell therapies, protein degraders, and radiopharmaceuticals.
Filing excerpt
We concentrate our R&D efforts in the following disease areas with significant unmet medical needs: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases...
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kdigitalTransformationGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/a3ceab5d-04ff-4a87-ae25-2e03e36cedda returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "a3ceab5d-04ff-4a87-ae25-2e03e36cedda",
"signal_type": "sec-10k",
"signal_subtype": "digitalTransformation",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "The company is concentrating its R&D efforts in high-unmet-need areas like oncology and immunology, utilizing advanced, data-intensive platforms such as cell therapies, protein degraders, and radiopharmaceuticals. This strategic shift to build its next generation of products creates opportunities for vendors providing specialized clinical trial, data management, and lab automation solutions.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "BMY pivots R&D to novel modalities like cell therapy, ADCs, and radiopharmaceuticals",
"excerpts": "We concentrate our R&D efforts in the following disease areas with significant unmet medical needs: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases...",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Multi-year tech investment",
"signal_category": "strategic",
"technologies_mentioned": [
"cell therapies",
"protein degraders",
"ADCs",
"radiopharmaceuticals",
"biologics",
"CAR-T cell therapies"
]
}
}
curl https://signals.autobound.ai/v1/signals/a3ceab5d-04ff-4a87-ae25-2e03e36cedda \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.